GLP-1 drugs for kids: what the pediatric obesity data actually shows

What did @dra.monserguez.endoped actually say?

Here is the uncomfortable truth: the transcript attached to this video is completely incoherent. The auto-generated captions appear to have catastrophically failed, producing text about "the American government" and "the East Coast of Greece" that has no relationship to the Spanish-language video or its caption. We cannot quote the creator directly from the transcript because the transcript does not reflect what was spoken.

What we can work with is the caption, which states that Saxenda and Wegovy are "used with medical criteria, accompaniment, and a lot of family love" in the context of pediatric obesity. The creator identifies as a pediatric endocrinologist posting under the handle EndoKids. That framing, combined with the hashtags obesidadniños (childhood obesity), saxenda, and wegovy, tells us the video is making an implicit case for GLP-1 receptor agonist use in children and adolescents. That is a legitimate and evolving conversation in medicine. It also carries real risks if handled carelessly on social media.

Does the science back this up?

Partially, yes, but the approval landscape is narrower than a casual social media post might suggest. Liraglutide (Saxenda) received FDA approval in 2020 for adolescents aged 12 and older with a BMI at or above the 95th percentile. Semaglutide (Wegovy) received FDA approval for the same age group in 2022. These are not off-label experiments.

The pivotal trial for adolescent semaglutide, published by Weghuber et al. (2022) in the New England Journal of Medicine, found that 56 weeks of 2.4 mg weekly semaglutide reduced BMI by 16.1% compared to 0.6% in the placebo group among adolescents aged 12 to 17. That is a clinically meaningful difference. The liraglutide data from Kelly et al. (2020, NEJM) was more modest, showing roughly 4.5% greater BMI reduction versus placebo. Side effect profiles in both trials were consistent with adult data, predominantly gastrointestinal symptoms, with no new safety signals identified in the trial periods. Long-term pediatric data, however, remains thin. These are not 10-year studies.

What did they get wrong (or right)?

The caption gets the broad strokes right. Both medications do have regulatory approval for adolescent use. Medical supervision is genuinely required, and family involvement in pediatric obesity treatment is supported by behavioral science. A 2023 review by Cuda and Censani in Obesity Reviews confirmed that multidisciplinary, family-centered approaches improve outcomes when combined with pharmacotherapy.

What the post cannot be credited with, because the transcript is unreadable, is any nuanced discussion of who qualifies, what the contraindications are, or what monitoring looks like. Posting the brand names Saxenda and Wegovy alongside the hashtag obesidadniños without that context carries real potential for misuse. Parents of children who do not meet clinical criteria may pursue these medications based on social media exposure. That is not a hypothetical. A 2023 survey published in Obesity Medicine found that 34% of caregivers who asked about GLP-1 drugs for their children cited social media as their primary information source.

The "mucho amor familiar" framing is warm but it does not substitute for clinical gatekeeping language. A pediatric endocrinologist should know this better than most.

What should you actually know?

Saxenda and Wegovy are FDA-approved for adolescents 12 and older who meet specific BMI and comorbidity criteria. They are not approved for younger children in the United States, though research is ongoing. Neither drug is a standalone treatment. Every major trial included lifestyle intervention as a co-intervention, and dropping that component predictably reduces results.

These medications are not without risk. Pancreatitis, gallbladder disease, and potential thyroid c-cell effects carry FDA black box warnings. In adolescents, bone density and growth plate implications during treatment have not been fully characterized over multi-year periods. The American Academy of Pediatrics 2023 clinical practice guideline does endorse pharmacotherapy as one component of intensive obesity treatment for qualifying adolescents, but it is explicit that this requires specialist oversight, not a TikTok recommendation.

If you are a parent seeing this content and wondering whether your child qualifies, the answer requires a pediatric endocrinologist or obesity medicine specialist, not a social media caption. Compounded versions of semaglutide or liraglutide are not equivalent to the brand-name drugs and should not be considered interchangeable, particularly in pediatric populations where dosing precision matters.

• Saxenda (liraglutide) is FDA-approved for ages 12 and up with BMI at or above the 95th percentile plus at least one weight-related comorbidity.
• Wegovy (semaglutide) received the same age-group approval in 2022 following the Weghuber et al. NEJM trial.
• Neither drug is approved for children under 12 in the US as of 2024.
• Family-centered behavioral support improves pharmacotherapy outcomes but does not replace clinical screening.
• Long-term pediatric safety data beyond 1 to 2 years remains limited.